CN116194136A - 用于促进水化的制剂及其使用方法 - Google Patents

用于促进水化的制剂及其使用方法 Download PDF

Info

Publication number
CN116194136A
CN116194136A CN202180056268.5A CN202180056268A CN116194136A CN 116194136 A CN116194136 A CN 116194136A CN 202180056268 A CN202180056268 A CN 202180056268A CN 116194136 A CN116194136 A CN 116194136A
Authority
CN
China
Prior art keywords
aspartic acid
range
molar ratio
serine
isoleucine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056268.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·维德亚瑟格
A·格罗舍
徐晓东
林珊珊
S·修福隆特
R·肯尼菲克
S·加托
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entelinco LLC
University of Florida Research Foundation Inc
Original Assignee
Entelinco LLC
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entelinco LLC, University of Florida Research Foundation Inc filed Critical Entelinco LLC
Publication of CN116194136A publication Critical patent/CN116194136A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Nutrition Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN202180056268.5A 2020-07-02 2021-07-01 用于促进水化的制剂及其使用方法 Pending CN116194136A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047300P 2020-07-02 2020-07-02
US63/047,300 2020-07-02
PCT/US2021/040090 WO2022006397A1 (en) 2020-07-02 2021-07-01 Formulations for promoting hydration and methods of use thereof

Publications (1)

Publication Number Publication Date
CN116194136A true CN116194136A (zh) 2023-05-30

Family

ID=79314908

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056268.5A Pending CN116194136A (zh) 2020-07-02 2021-07-01 用于促进水化的制剂及其使用方法

Country Status (11)

Country Link
US (2) US12357600B2 (https=)
EP (1) EP4175662A4 (https=)
JP (1) JP2023533617A (https=)
KR (1) KR20230047371A (https=)
CN (1) CN116194136A (https=)
AU (1) AU2021300188A1 (https=)
BR (1) BR112022027124A2 (https=)
CA (1) CA3184691A1 (https=)
IL (1) IL299488A (https=)
MX (1) MX2023000004A (https=)
WO (1) WO2022006397A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11878073B1 (en) * 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3916903A1 (de) * 1989-05-24 1991-02-28 Leopold Pharma Gmbh Waessrige zusammensetzung fuer die parenterale ernaehrung
JP2002275059A (ja) * 2001-03-15 2002-09-25 Inst Of Physical & Chemical Res 腎機能障害改善用アミノ酸組成物
WO2010017403A2 (en) * 2008-08-06 2010-02-11 Immunopath Profile, Inc. Therapeutic compositions, devices and methods for observing treated tissues
CN102170876B (zh) * 2008-10-06 2013-12-04 株式会社明治 含有氨基酸组合物作为有效成分的耐力提高剂、抗疲劳剂或疲劳恢复剂
KR101758424B1 (ko) * 2010-09-24 2017-07-14 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 위장 기능을 증진시키기 위한 물질 및 방법
HK1204290A1 (en) * 2012-02-08 2015-11-13 University Of Florida Research Foundation, Inc. Materials and methods for treating diarrhea
EP3459540A1 (en) * 2014-11-24 2019-03-27 Entrinsic Health Solutions, Inc. Amino acid compositions for the treatment of symptoms of disease
EP3522882A4 (en) * 2016-10-04 2020-06-24 The University of Florida Research Foundation Incorporated AMINO ACID COMPOSITIONS AND USES THEREOF
CN109218470B (zh) * 2017-07-05 2021-08-24 中兴通讯股份有限公司 移动终端及其控制方法
WO2019070753A1 (en) * 2017-10-02 2019-04-11 University Of Florida Research Foundation, Incorporated AMINO ACID COMPOSITIONS AND METHODS FOR TREATING DIARRHEA

Also Published As

Publication number Publication date
US12357600B2 (en) 2025-07-15
US20230149335A1 (en) 2023-05-18
US20250367154A1 (en) 2025-12-04
MX2023000004A (es) 2023-03-06
CA3184691A1 (en) 2022-12-30
WO2022006397A1 (en) 2022-01-06
KR20230047371A (ko) 2023-04-07
AU2021300188A1 (en) 2023-02-02
EP4175662A1 (en) 2023-05-10
JP2023533617A (ja) 2023-08-03
BR112022027124A2 (pt) 2023-03-07
EP4175662A4 (en) 2024-07-17
IL299488A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
US11357747B2 (en) Amino acid compositions for the amelioration of symptoms of hangover
BR112017010483B1 (pt) Composição de reidratação oral e uso da mesma
Sen et al. General overview to treatment of strong ion (metabolic) acidosis in neonatal calves with diarrhea
US20250367154A1 (en) Formulations for promoting hydration and methods of use thereof
Nagy et al. Colostrum protein concentrate enhances intestinal adaptation after massive small bowel resection in juvenile pigs
WO2016112552A1 (zh) 牛磺酸在预防和/或治疗由冠状病毒属和/或轮状病毒属病毒引发的疾病中的应用
Di Girolamo et al. Cystoscopic diagnosis of polypoid cystitis in two pet rabbits
US20230210798A1 (en) Formulations and methods for treating diarrhea
CN108273038B (zh) 防治肠型放射病的药物组合物
Lionet et al. Chronic urine acidification by fludrocortisone to treat infectious kidney stones
US20240009160A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of cancer
Smith Myth: One oral electrolyte is just as good as another
JP5477413B2 (ja) 分岐鎖アミノ酸の心不全適応
JP5076327B2 (ja) 分岐鎖アミノ酸の心不全適応
Smith Treating scouring beef and dairy calves
JP2025533647A (ja) 腸感染症の治療方法
Kabadi et al. Goiter: A Review of Pathophysiology and Management
Pal MY BELOVED PARENJTS
JPH07285859A (ja) 鎮痛作用増強剤
CZ20001999A3 (cs) Přípravky a způsoby pro zvyšování koncentrace a/nebo pohyblivosti lidských spermatozoí
HK1209329B (en) Use of a composition comprising meglumine or a salt thereof for manufacturing a medicament for reducing or preventing the increase of triglyceride levels

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Country or region after: U.S.A.

Address after: Florida, USA

Applicant after: University OF FLORIDA RESEARCH FOUNDATION, INC.

Applicant after: Amylev Limited

Address before: Florida, USA

Applicant before: University OF FLORIDA RESEARCH FOUNDATION, INC.

Country or region before: U.S.A.

Applicant before: Entelinco LLC